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Abstract
Adoptive T cell therapies can produce objective clinical responses in patients with hematologic and
solid malignancies. Genetic manipulation of T lymphocytes has been proposed as a means of
increasing the potency and range of this anti-tumor activity. We now review how coupling expression
of transgenic receptors with countermeasures against potent tumor immune evasion strategies is
proving highly effective in pre-clinical models and describe how these approaches are being
evaluated in human subjects.
INTRODUCTION
Infusion of antigen-specific cytotoxic T lymphocytes (CTLs) has proven safe and apparently
effective for the prophylaxis and treatment of viral infections such as cytomegalovirus (CMV)
[1–3], adenovirus (Adv) [3], and Epstein-Barr virus (EBV) [4,5] that arise in
immunocompromised patients. This therapeutic approach has also been extended to the
treatment of cancer and has shown some success in patients with melanoma [6] and EBV-
associated malignancies such as Hodgkin’s lymphoma [7,8] and nasopharyngeal carcinoma
[9,10]. This form of “personalized medicine” is now being explored in both early- and late-
stage clinical trials. Recent improvements in molecular biology have increased the potential
applications and effectiveness of this therapeutic approach by allowing the genetic
modification of T cells using genes which confer properties such as new antigen specificity
(αβT cell receptors – αβTCRs [11] or chimeric antigen receptors – CARs [12]), improved
homing to tumor sites [13], increased resistance to tumor immune evasion strategies [14,15],
and the ability to up- or down- regulate proliferation of the infused cells [16,17]. This review
evaluates recent improvements in T cell engineering and describes their current clinical impact
and their future potential as cancer therapeutics.
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T CELL IMMUNITY AGAINST TUMOR CELLS
The development of an anti-tumor T cell mediated immune response is a multi step process in
which tumor-associated antigens (TAAs) expressed by the tumor cells are processed and
presented by professional antigen presenting cells (APCs) to circulating T cells, which become
activated. The quality and potency of this T cell response will depend on the nature of the
antigen presented, the functionality of the APC itself and the cytokines and co-stimulatory
interactions that occur in the T cell/APC microenvironment [18]. Once activated, TAA-specific
effector T cells can migrate to the tumor site and target malignant cells expressing the cognate
antigen epitope displayed in the context of a major histocompatibility complex (MHC)
molecule [18].
The potency and protective abilities of endogenous tumor-specific T cells are evident from
studies of immunosuppressed individuals with dysfunctional or absent T cells (such as HIV-
infected patients or transplant recipients), who are at increased risk of developing a range of
malignances such as non-Hodgkin’s lymphoma (NHL) [19], Kaposi’s sarcoma, and invasive
cervical cancer [20]. The importance of the immune system for prevention and control of
tumors in immunocompetent individuals, however, is much more controversial [20]. When
tumors arise in otherwise normal subjects, the conclusion is that specific T cells were either
not induced in vivo, or were unable to destroy the malignant cells. Many of the antigens
expressed by tumor cells are not unique to cancer cells and are instead expressed in normal
tissues [21]. Consequently, the immune system may have antigen specific T cells that recognize
the tumors, but that are rendered unresponsive or tolerant [22]. Efforts to break this
unresponsiveness by aggressive vaccination have often failed [23]. An alternative approach is
to adoptively transfer non-tolerant T cells that have been expanded in vitro in an environment
that is capable of breaking their tolerant state and inducing potent effector cells. For example,
EBV-specific CTLs can be generated ex vivo from EBV-specific T cell precursors circulating
in the peripheral blood of individuals with EBV+ malignancies [7,8]. Once returned to the
patients, these effector T cells can effectively eradicate tumors that had been resistant to their
endogenous precursors, even though both share the same antigenic specificity [7,8]. Similarly,
autologous tumor-infiltrating T lymphocytes (TIL) obtained from melanoma patients,
expanded ex vivo and infused, have produced clinical response in about 50% of treated
individuals [6,24].
Breaking tolerance alone, however, is often insufficient for CTLs to be able to exert potent in
vivo anti-tumor effector function. As illustrated in Fig. (1), malignancies have evolved a
number of evasion strategies to mitigate tumor-directed T cell reactivity. These include (i) the
secretion of immunosuppressive molecules like TGF-β, interleukin (IL)-10, and IL-13, which
inhibit effector T cells [25], (ii) modulation of MHC and costimulatory molecules to prevent
antigen-specific T cell recognition [25], (iii) recruitment of regulatory T cells (Tregs) which
inhibit effector T cells by direct cell-to-cell contact or by the production of soluble factors
[26–29], (iv) constitutive expression of the tryptophan-depleting enzyme, indoleamine 2,3-
dioxygenase (IDO) that prevents lymphocyte proliferation [30], (v) expression of Fas ligand
which can induce premature apoptosis of activated T cells through Fas-Fas ligand interaction
[31] and, (vi) expression of inhibitory cell surface molecules such as PD-L1 (program death
ligand), which interacts with PD-1 expressed on activated T cells, and induces T cell exhaustion
[32,33].
Genetic modifications have been devised to act as countermeasures to these immune evasion
mechanisms, thereby improving the effectiveness of tumor-specific T cells in vivo.
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METHODS OF GENE MODIFICATION (VIRAL AND NON VIRAL)
Effective genetic modification of T cells requires systems that produce adequate gene delivery
and adequate expression of functional transgenes. While the level and duration of expression
required for a given transgene depends on the specific function required, in general, the
sustained modification of highly proliferative cells such as the T lymphocytes calls for an
efficient integrating vector system that produces at least moderately high expression. The great
majority of studies to date have therefore used retroviral vectors (Moloney or Lentivirus based)
[5,34–38] but the more recent development of integrating plasmids has renewed interest in the
use of non viral approaches.
Though widely used in clinical studies, viral vectors are expensive to produce and test, and
there is often a requirement for onerous and prolonged follow up of treated patients that further
adds costs and complexity. Non viral vectors (eg. DNA plasmids) though cheaper to produce
and test, require physical (e.g. electroporation) or chemical (e.g. liposomes) approaches to
mediate gene transfer [39–41]. Until recently, DNA plasmids also integrated with extremely
low efficiency, and so were associated with rapid disappearance in highly proliferating T cells.
The discovery of transposon-based gene delivery systems overcomes this limitation by
combining transposons and transposases in a plasmid with the gene of interest. Systems such
as Sleeping Beauty [42,43] and Piggybac [44] are currently used to gene modify T
lymphocytes.
GENETIC ENGINEERING OF T CELLS
Gene transfer can be used to (i) improve the intrinsic biological activity of T cells (e.g. confer
tumor specificity, enhance cytokine production or improve T cell migration), (ii) provide
resistance to the immunosuppressive tumor microenvironment, (iii) enhance the safety of
adoptively transferred T cells (e.g. addition of suicide genes), or (iv) enable T cell marking or
imaging studies.
TRANSFER OF ANTIGEN SPECIFICITY TO THE T CELLS
Because most TAA are either “self” antigens or “naïve” targets for the immune system, the
generation of tumor-reactive T cells from cancer patients is often difficult or impossible, even
under optimal conditions of ex vivo culture [45,46]. To overcome this problem, investigators
have genetically modified T cells to allow them to recognize antigens expressed by tumor cells.
The two most common approaches are (a) expression of CARs that recognize tumors through
single-chain variable fragments (scFv) isolated from specific antibodies [47] and (b) gene
modification with α and β TCR chains cloned from TAA-specific T cell clones with high
antigen avidity [48].
Chimeric Antigen Receptors (CARs)
CARs are artificial receptors directed against antigens expressed on the cell surface of tumor
cells, but with reduced or absent expression on normal tissues, thereby minimizing “off target”
effects. First generation CARs are composed of the single-chain variable fragment (scFv)
obtained from a specific antibody linked, via an extracellular spacer, with a transmembrane
region and the intracytoplasmatic domain of the CD3ζ [47] (Fig. 2). The endodomain is
responsible for transmitting the signal from the chimeric receptor and triggering
phosphorylation of ITAM motifs, and the subsequent induction of T cell cytotoxic activity.
CARs can combine the antigen specificity of an antibody with the lytic capacity of T cells and
mediate antigen recognition in an MHC-unrestricted fashion. They also extend the range of
antigens that can be recognized by T cells to include carbohydrates and glycolipids [49–51].
The overall efficacy of CAR-modified T cells against tumor target cells is the result of a
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complex interaction that includes the avidity of the scFv, the level of expression of CAR
molecules on T cells, the density of antigen expressed on the target cells, and the position of
the epitope on the target molecule in respect to the length and flexibility of the extracellular
spacer sequence incorporated in the CAR.
Clinical Studies with CARs
CAR-expressing T cells can specifically recognize and respond to soluble, immobilized and/
or tumor antigens expressed on target cells, and to date a range of CARs targeting a variety of
surface molecules expressed by many solid tumors and hematological malignancies have been
developed [52–61] (Table 1). While preclinical studies demonstrate that T cells expressing
CARs can eliminate tumors in murine models [56,61,62], clinical trials with “first generation”
CARs, containing only the CD3ζ signaling domain, were disappointing [39,63,64]. Following
engagement with tumor antigens, the CD3ζ endodomain provides insufficient co-stimulatory
signaling to the T cells to produce activation, proliferation and cytokine release, while the
tumor cells themselves lack sufficient costimulatory signals to accomplish this through the
endogenous counter-receptors on CAR-modified T cells [65]. This led to the development of
“second generation” CARs, in which additional intracellular co-stimulatory endodomains are
added to enhance their function. These endodomains are derived from costimulatory molecules
such as CD28, ICOS, CD134 and CD137 [56,66–70], and T cells expressing these
endodomains produce a broad array of cytokines such as IL-2 and TNF-α upon chimeric
receptor engagement. These cytokines enhance the proliferation and persistence of genetically
modified T cells after recognition of their CAR specific target. More recently “third generation”
CARs, characterized by the presence of two costimulatory molecules in addition to the
CD3ζ, have been developed [70,71]. Carpenito and colleagues formally compared the potency
of a CAR linked to a range of different endodomains and found that the simultaneous expression
of CD137 (41BB) and CD28 endomains was more potent than either endodomain alone [72].
It remains to be demonstrated whether the “superphysiological” activation of T cells also
increases the toxicity of CAR-modified T cells.
Factors other than inadequate expression of costimulatory endodomains can result in poor in
vivo persistence of CAR-modified T cells. Since most CARs are derived from murine
antibodies, the chimera itself can induce an immune response in vivo following adoptive
transfer. Lamers and colleagues reported the development of anti-scFv antibodies in three
patients treated with T cells expressing a CAIX-specific CAR [58]. Similarly, Kershaw and
colleagues observed a CAR-specific antibody response in a patient treated with T cells
modified with a CAR directed against the ovarian-associated α-folate receptor (α-FR) [57].
Although this phenomenon has not been observed for all patients treated with CARs, the future
use of humanized single chains may reduce the risk of premature deletion of T cells due to
immune responses.
CAR-modified T cells may cause significant in vivo toxicities, such as the “on target antigen
but off target tissue” toxicity. Lamers et al. reported the development of cholestasis following
the infusion of T cells modified with a CAR targeting the carbonic anhydrase as treatment for
renal cell carcinoma as biliary epithelial cells also express carbonic anhydrase [58]. Brentjens
et al. recently reported renal and respiratory failure in a patient with B-cell chronic lymphocytic
leukemia treated with a single dose of 3×107/kg of T cells modified with a second generation
CAR targeting the CD19 molecule. This serious adverse event occurred when T cells were
infused after high doses of cyclophosphamide to induce host lympohodepletion and may have
been due to a cytokine storm or to rapid tumor lysis [73].
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T Cell Receptor α/βTCRs
T cells can be genetically modified to express transgenic α and β TCR chains, which have been
isolated from T cell clones specific for tumor-associated antigens including MART-1,
MAGE-3, MDM2, and WT-1 [11,74,75]. Both chains can be accommodated in a single
retroviral or lentiviral vector, and transfer of the tumor-specific αβTCR to autologous mitogen-
activated T cells allows rapid production of large numbers of tumor peptide-specific T cells.
These gene modified T cells acquire MHC-restricted cytotoxic activity against tumor cells
expressing the specific epitope. In most examples to date, polyclonal T cells are manipulated
to express a second, transgenic, αβTCR in addition to their native αβTCR [11,74]. The presence
of two pairs of receptors in a single cell leads to unwanted cross pairing between endogenous
α and transgenic β chains (and vice versa), reducing the affinity of the transgenic receptor for
the desired target antigen and potentially creating new and unwanted reactivities [48].
Investigators have manipulated the sequences of the transgenic chains to favor their linkage,
and have also tried introducing the receptors into TCR negative effector lymphocytes [76,
77]. At present it is unclear how valuable these approaches will be.
T cells expressing a transgenic αβTCR have been studied in clinical trials of patients with
melanoma. Investigators at the National Cancer Institute demonstrated that adoptive transfer
of polyclonal T cells transduced with a retroviral vector encoding the αβTCR chains specific
for an HLA-A2 restricted MART-1 peptide induced objective clinical response in 13% of the
patients [11]. In an effort to increase the frequency of significant tumor responses, the same
investigators infused T cells that expressed higher affinity transgenic αβTCRs specific for
MART-1 or gp100 peptides [78]. Disappointingly, this strategy only modestly increased the
tumor response rate but significantly exacerbated toxicity. The majority of patients developed
skin rush, uveitis and hearing loss, attributed to an immune attack on normal melanocytes
present in the skin, eye and inner ear [78]. Hence potent T lymphocytes can be generated by
appropriate genetic modification, but toxicity may become increasingly evident as potency
increases, particularly if the targeted antigen is not unique to the malignant cells.
GENETIC MODIFICATION OF T CELLS TO ENHANCE PERSISTENCE
Though antigen specificity can be readily conferred using genetic modification, once infused,
the tumor-specific T cells must expand in vivo and/or persist until all malignant cells have been
eliminated. T cell proliferation requires continued antigenic stimulation, either via direct
interaction with tumor cells or through professional APCs that cross-present tumor antigens,
and the presence of appropriate cytokines. Moreover, following in vivo expansion, a proportion
of the tumor-specific T cells should ideally enter the memory T cell compartment to provide
long-term protection. To prevent these events, tumors have developed potent strategies to avoid
effective antigen presentation, inhibit T cell proliferation, and prevent T cell entry into the
memory compartment [25]. As a consequence, both preclinical and clinical studies have shown
that transferred cells have limited capacity to expand and persist in vivo. Several
countermeasures have been developed against these unwanted tumor effects on immune
persistence. These include: i) genetic modification of T cells to improve proliferation and
survival, ii) the infusion of T cells with memory-type characteristics [79], and iii) genetic
modification of infused cells to withstand the tumor microenvironment (Fig. 3).
IMPROVING PROLIFERATION AND SURVIVAL OF EFFECTOR T CELLS
Cytokines
Cytokines such as IL-2 promote T effector cell expansion and survival, and systemic
administration can support adoptive T cell therapies [6,24]. However, prolonged administration
of recombinant IL-2 can also cause significant toxicity [6,24] and expand Tregs which
antagonize the beneficial effects of the cytokine on T effector cells [80]. We and others have
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explored alternative methods to expand T cells in vivo, by genetically modifying T cells with
retroviral vectors encoding the cytokines IL-2 or IL-15 to produce cells which are cytokine
self-sufficient and self-sustaining [16,81,82]. Extensive characterization demonstrated that
these cytokine-transgenic cells conserved their antigen specificity, phenotype and function and
also retained their dependence on antigenic stimulation for continued expansion. Importantly,
genetically modified T cells had enhanced persistence and superior anti-tumor activity in
vivo compared to unmodified cells [16].
T cell growth and survival can also be increased by engineering cells to respond to cytokines
in the tumor environment, or which can be safely administered as a recombinant protein, but
which do not normally induce T cell growth [83]. We investigated this option by genetically
restoring the ability of activated antigen-specific CTLs to respond to IL-7, a cytokine that has
been safely administered to human subjects without apparent enhancement of Treg cell number
and function [83–85]. Unfortunately, IL-7 has only limited activity on antigen-specific T cells,
since IL-7Rα expression is rapidly downregulated by naïve T cells once they have received
antigenic stimulation [17]. By forcing the expression of IL-7Rα in antigen-specific T cells, we
selectively expanded them in vitro and in vivo in response to IL-7, without inducing unwanted
proliferation of other T cell subsets [17]. Clinically, the IL-7 required to support expansion of
the transgenic receptor-expressing CTLs may derive either from the physiological release of
the cytokine in a lymphodepleted host or from the administration of the recombinant protein.
Pro-survival genes
T cell survival can also be increased by overexpressing the human telomerase reverse
transcriptase (hTERT) gene [86]. Although this approach greatly increases the number of
population doublings of transduced T cells by preventing telomere erosion, it may also favor
genomic instability and limit its safety and hence clinical application. An alternative means of
increasing the persistence of infused T cells is to modify them with anti-apoptotic genes, such
as Bcl-2 and Bcl-xL, which increase T cell resistance to death and IL-2 cytokine withdrawal
[87].
Co-stimulation
T cell proliferation and survival require antigenic stimulation by APCs expressing co-
stimulatory molecules. Many tumor cells lack expression of co-stimulatory molecules, such as
CD80 and CD86, and substantially reduce the opportunity of T cells to successfully encounter
the antigen in a suitably co-stimulatory environment [25,88]. One way to circumvent this
problem is to use CARs or transgenic αβTCRs to retarget virus-specific CTLs, rather than
“random” T cells. Such virus-specific CTLs should receive optimal activation and co-
stimulation following engagement of their native (virus specific) αβTCRs with viral latent
antigens expressed by professional APCs, thus enabling superior anti-tumor activity mediated
by their tumor reactive transgenic receptor. This hypothesis has been tested in a clinical trial
performed at our institution, in which we compared the longevity of polyclonal activated T
cells and polyclonal EBV-specific CTLs each expressing a CAR targeting the GD2 antigen,
which is expressed on neuroblastoma [12,60]. The EBV-specific CTLs remained detectable
substantially longer (>18months) than their activated T cell counterparts (<1 month),
suggesting the beneficial effects of co-stimulation of EBV-specific CTLs provided by APCs
expressing EBV-latent antigens [12].
An alternative means for providing T cell co-stimulation is to force the expression of co-
stimulatory ligands, such as CD80 and 4-1BBL, for the co-stimulatory receptors they already
possess [89]. Post-infusion, these molecules will insure there is “autocostimulation” and a
bystander “transcostimulation”, which substitutes for the lack of appropriate co-stimulation
from the tumor cells. Preclinical studies have shown that incorporation of these molecules in
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CAR-modified T cells enhances their ability to produce effector cytokines (IFNγ, IL-2,
TNFα) and, in an in vivo mouse model, promotes tumor rejection in mice with large tumor
burden [89].
Resistance to immunosuppressive drugs
In many of the settings in which adoptively transferred T cells will be used, patients are also
receiving immunosuppressive and/or T cell inhibitory agents, which can adversely affect the
persistence, functional capabilities and survival of adoptively-transferred T cells. For example,
solid organ transplant recipients require continued administration of immunosuppressive drugs
such as tacrolimus to prevent graft rejection. However, since these agents also impair
endogenous T cell function, these patients are at high risk of developing virus-associated
complications including EBV-post-transplant lymphomas [90]. Although adoptive transfer of
EBV-specific CTLs can still be effective in these patients, the cells do not persist long-term
[91–93]. Strategies to make antigen-specific CTLs resistant to the effects of
immunosuppressive drugs have been recently developed and include stable siRNA-mediated
knock-down of the FK506-binding protein 12 (FKBP12) [94], the key protein that binds
FK506, and overexpression of calcineurin mutants [95]. Both strategies protect virus-specific
CTLs from inhibitory effects whilst preserving their anti-viral activity.
NEUTRALIZING THE HOSTILE TUMOR MICRO-ENVIRONMENT
Genetic modification of T cells can also be used to counteract the immune-inhibitory tumor
microenvironment that can neutralize adoptively transferred antigen-specific CTLs. One of the
most widely used tumor evasion strategies is local secretion of TGF-β by the tumor or its
stromal elements [25]. TGF-β is a multifunctional cytokine that, among other activities, limits
T cell proliferation and effector function and induces tolerance [96]. Antigen-specific CTLs
modified to express a dominant-negative TGF-β receptor type II (dnTGF-β-RII) are resistant
to the antiproliferative effects of TGF-β in vitro and in vivo [14], and expression prolongs their
persistence and enhances tumor elimination in mice bearing TGF-β-expressing tumors [14,
97]. However, the gene modified T cells persisted only as long as the mice were restimulated
with antigen, offering reassurance that the cells safely maintained their antigen dependence.
A clinical trial to assess the safety and efficacy of dnTGF-β-RII-modified tumor-specific CTLs
for the treatment of patients with relapsed/refractory Hodgkin’s lymphoma has recently opened
at our institution.
Indoleamine 2,3-dioxygenase (IDO), is an enzyme catalyzing the initial step in the catabolism
of tryptophan along the kynurenine pathway [30]. T cells are particularly sensitive to
tryptophan shortage, a property exploited by a number of tumors that secrete this enzyme either
constitutively or in the presence of proinflammatory cytokines [30,98,99]. The inhibitory
effects of IDO in T cells may be overcome by gene modification aimed to downregulate GCN2,
a major component of IDO-mediated suppression. Munn and colleagues showed in pre-clinical
studies that GCN2-knockout cells were refractory to IDO-induced anergy [100].
Fas ligand (FasL/CD95L) is a member of the tumor necrosis factor (TNF) superfamily and can
trigger apoptosis through cross-linking of its receptor Fas (CD95). Many tumors express Fas
ligand (FasL) as part of their tumor evasion arsenal, and researchers have suggested that this
allows “immune privilege” because activated effector T cells express Fas on their cell surfaces
and so are sensitive to Fas-mediated apoptosis, impairing T cell-mediated tumor rejection
[101–103]. To overcome this, stable gene transfer of small interfering RNA (siRNA) designed
to down regulate Fas can render T cells resistant to the apoptotic effects of FasL-expressing
tumor cells [15].
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At present, we do not know the best means of neutralizing the hostile tumor environment, and
it is likely that a combination of the above countermeasures will need to be employed.
Nonetheless, as we progressively accrue clinical data to add to the information provided by
preclinical models, it should become possible to discern the optimal approach.
REDIRECTING T CELL MIGRATION
The interaction of secreted chemokines and chemokine receptors on the cell surface of the T
cells plays a significant role in modulating the in vivo migration of T cells [104,105]. Tumors
can generate a chemokine milieu that significantly modifies the trafficking of Th1, Th2 cells
and Tregs [27]. Malignant Hodgkin’s lymphoma cells, for example, produce TARC and MDC
which strongly attract Th2 and Tregs since these T cell subsets constitutively express CCR4,
the receptor for both chemokines [106,107]. By contrast, Th1 cells lack CCR4 and hence
migrate poorly to HL tumor cells. Gene transfer offers the opportunity to re-shape the migration
profile of Th1 cells so that they can exploit the tumor’s own escape mechanisms. We recently
produced effector CD8+ CTL migration to TARC+ tumors by transgenic expression of the
CCR4 receptor [13]. This genetic modification enhances the anti-tumor effects of Th1 cells
without apparent modification to their effector function [13]. Similar approaches could be
extended to other human malignancies in which a signature chemokine pattern can be identified
[108].
GENETIC MODIFICATION OF T CELLS TO IMPROVE SAFETY
Suicide genes
The genetic approaches described above can enhance the expansion and persistence of T cells,
change their homeostatic properties, alter their trafficking pattern and re-direct their antigen
specificity to recognize specific antigens. Inevitably, these changes will be associated with an
increased risk of direct toxicity and of unwanted proliferation, and even cell transformation
due to insertional mutagenesis [109]. To allow the rapid and complete elimination of infused
cells, several groups have evaluated safety switches or suicide genes, which can be triggered
should toxicity occur.
The best validated of the suicide genes is thymidine kinase from herpes simplex virus I (HSV-
tk) [35,110]. This enzyme phosphorylates the nontoxic prodrug ganciclovir, which then
becomes phosphorylated by endogenous kinases to GCV-triphosphate, causing chain
termination and single-strand breaks upon incorporation into DNA, thereby killing dividing
cells. Several phase I-II studies have shown that Ganciclovir administration can safely
eliminate transferred HSV-tk-modified cells in vivo [110,111]. Unfortunately, the HSV-tk gene
product is itself immunogenic and can induce reactive T cells which may prematurely eliminate
the infused cells [112], compromising the persistence and hence efficacy of the transferred T
cells.
More recently, inducible Fas [113], Fas-associated death domain–containing protein (FADD),
and Caspase9 [114,115] molecules have been considered as alternative non-immunogenic
suicide genes. Each of these molecules can act as a suicide switch when fused with a FK-
binding protein (FKBP) variant that binds a chemical inducer of dimerization (CID), AP1903,
a synthetic drug that has proven safe in healthy volunteers [116]. Administration of this small
molecule results in cross-linking and activation of the proapoptotic target molecules. Up to
90% of T cells transduced with inducible Fas or FADD undergo apoptosis after exposure to
CID [113]. While promising, elimination of 90% of transduced cells may be insufficient to
ensure safety of genetically modified cells in vivo. Moreover, death molecules that act upstream
of most apoptosis inhibitors may be ineffective when tried in other cell types. Modification of
the late-stage apoptosis pathway molecules such as caspase9 may be preferable [114]. This
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suicide gene can be stably expressed in human T cells without compromising their functional
and phenotypic characteristics [16,114]. The cells are highly sensitive to the CID, which can
induce apoptosis in up to 95% of transduced cells [16,115]. This suicide gene strategy is
currently being tested clinically at our institution as a means of eliminating adoptively-
transferred polyclonal T cells after haploidentical transplantation.
Transgenic expression of the CD20 moleucle, which is normally expressed on B cells, has also
been postulated as suicide gene for T cell therapies [117]. This strategy relies on the clinical
availability of a humanized anti-CD20 antibody (Rituximab) which is widely used to eliminate
both normal and neoplastic B cells expressing the CD20 antigen. Thus, infusion of T cells
expressing human CD20 and subsequent in vivo administration of Rituximab should efficiently
eliminate the infused T cell population, although it will also eliminate normal B cells.
Targeted integration
Reports of leukemia development caused by insertional mutagenesis using retroviral vectors
for stem cell modification [109,118], have spurred development of safer techniques for
modifying cell DNA sequences, either by pre-determining the integration site of the transgene
or by using modified vectors with a safer profile.
Zinc finger nucleases (ZFN) are artificial restriction enzymes generated by fusing a zinc finger
DNA-binding domain to a DNA-cleavage domain. The underlying technology is known as
gene targeting and is based on the cellular homologous recombination (HR) pathway, which
has evolved to promote genetic recombination during meiosis and the repair of DNA double
strand breaks. These ZFN can be customized to generate a DNA double stand break at a
preselected site in the human genome and their development has paved the way for both knock-
out and knock-in strategies in gene therapy. The therapeutic efficacy of this strategy is currently
being evaluated in CD4+ T cells, in which disruption of the chemokine receptor 5 is expected
to protect the T cells from infection with the HIV virus. Infected mice engrafted with ZFN-
modified human CD4+ T cells had a lower load of HIV1 and higher CD4+ T cell counts than
controls [119]. Validation studies using this approach for therapeutic transgenes are in the
planning stages. Researchers are also moving away from Moloney based retroviral vectors to
lentivectors, which appear less prone to integrate near transcription start sites and may thereby
reduce the risk of oncogenesis [120].
T CELL MARKING AND IMAGING
Gene marking was first used clinically as a means of determining the persistence of infused T
cells in vivo, and to allow investigators to track their migration and association with adverse
effect such as GvHD, rather than as a tool to confer additional biological characteristics to cells
[5,34,37]. Initial trials included inclusion of integrants such as the neomycin resistance gene
[5,34] and non-functional proteins like the truncated nerve growth factor receptor [36].
Expression of genes that extend this conceptual approach and enable direct T cell imaging in
vivo are currently in development. For example, repetitive positron emission tomography and
computed tomography (PET-CT) imaging of T cells genetically labeled to express the HSV1-
tk reporter gene is possible in small and large animals using 2'-fluoro-2'-deoxy-1-β-D-
arabinofuranosyl-5-iodouracil (FIAU), 9-(4-[18F]fluoro-3-(hydroxymethyl)butyl)guanine
(18F-FHBG) or 2'-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil (18F-FEAU)
radiotracer [121–123]. Recently, Yaghoubi et al. [124] reported that 18F-FHBG PET can detect
HSV1-tk+ T lymphocytes infused loco-regionally into the site of tumor resection in a patient
with grade IV glioblastoma multiforme indicating that these methodologies may be extensively
clinically applicable in the future.
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T CELL MANUFACTURE (GMP CONSIDERATIONS)
Although the administration of ex vivo activated and expanded primary and antigen-specific
CTLs is associated with promising clinical results, there are several limitations to broader
implementation. A major practical constraint is the current complexity of production. T cell
proliferation in traditional cell cultureware is limited by requirements for nutrients and oxygen
(O2), and by accumulation of waste products such as carbon dioxide (CO2) and lactic acid so
that cultures must be fed and split regularly [125].
To improve cell output with minimal cell handling, a number of closed-system bioreactors
have been explored. Mechanical rocking or stirring increases the availability of O2 in the
culture, while media and nutrients can be exchanged by perfusion [126]. We have evaluated a
novel gaspermeable rapid expansion cultureware (G-Rex) developed by Wilson Wolf
Manufacturing, in which O2 and CO2 are exchanged across a silicone membrane at the base
of the flask [127]. Gas exchange from below allows an increased depth of medium above,
providing more nutrients and diluting waste. This system supports the expansion of antigen-
specific CTLs, as well as genetically modified T cells, is scalable, GMP-compliant, and reduces
the number of technician interventions approximately 4-fold while increasing the cell output
by 3–20-fold compared with conventional methods (Fig. 4).
CONCLUSIONS
To tip the balance of power away from the tumor and in favor of adoptively-transferred T cells
many groups have used genetic modification to improve target recognition, enhance T cell
persistence and migration, and to increase T cell resistance to the inhibitory tumor
microenvironment. Promising pre-clinical data are now being validated in current and future
human clinical trials. Even if successful, these therapies will ultimately be limited by the cost
and complexity of the cell manufacturing process and simplified and accelerated cell culture
systems are now in development and should help to make T cell therapy more accessible.
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Fig. 1. Tumor immune evasion strategies
Tumors have evolved complex mechanisms to subvert the cellular immune response, including
expression of FasL or PD-L1 which induce apoptosis or anergy in effector T cells, recruitment
of Tregs, secretion of TGF-β and other immunosuppressive cytokines which inhibit T cell
proliferation, constitutive expression of IDO by tumors and regulatory DCs, which depletes
tryptophan resulting in T cell anergy and downregulation or modulation of MHC and co-
stimulatory molecules.
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Fig. 2. Generation and function of CARs
Panel A) illustrates the structure of a chimeric antigen receptor, and expression by T cells after
gene transfer. After modification T cells can be redirected against tumor antigens and elicit a
cytotoxic effect. Panel B) shows the expression of a CAR on T cells after retroviral
transduction, by using a monoclonal antibody that recognizes the CH2CH3 extracellular
component of the protein. Panel C) Cytolysis by gene modified T cells: a B cell tumor (Daudi)
expressing green fluorescent protein (GFP) was cultured with non-modified T cells or T cells
transduced with a CAR targeting the κ-light chain of human immunoglobulins at a of ratio 5:1
(tumor cells to T cells). After 12 hours in culture, T cells modified with the CAR-κ have
destroyed the tumor.
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Fig. 3. Enhancing the anti-tumor effect of gene modified T cells
Several genetic modifications have been used to improve the antitumor efficacy and longevity
of T cells in vivo. These include transgenic expression of IL-2, IL-15, or IL-7Rα to improve
proliferation, over-expression of hTERT, Bcl-2, Bcl-XL to increase survival, expression of
CD80, 41BBL or modification of antigen-specific T cells to enhance co-stimulation,
overexpression of CCR4 to improve migration to tumor sites, expression of a dominant-
negative TGF-β receptor as well as downregulation of GCN2 or Fas on T cells to neutralize
the inhibitory tumor microenvironment.
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Fig. 4. Improving T cell manufacture
The figure shows the manipulations required for the expansion of antigen-specific CTLs using
conventional 24 well plates versus the G-Rex bioreactor. The G-Rex manufacturing increases
cell output with minimal manipulation and shortens the required CTL production time.
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Table 1
Chimeric Antigen Receptors
Specificity Tumor Target Reference
CEA Colorectal cancer [59]
EGP40 Colorectal cancer [128]
CD44v 7/8 Cervical carcinoma [129]
FBP Ovarian [130]
Le(Y) Ovarian epithelial [131]
MUC1 Breast, Ovary [132]






GD2 Neuroblastoma, Melanoma [12,60,139]
KDR Neo vasculature [140]
VEGF-R2 Neo vasculature [141]
CD30 Lymphoma [13,54,55]
CD33 Myeloid leukemia [68]
CD19 B cell malignancies [52,62,69]
CD20 B cell malignancies [142]
Kappa light chain B cell malignancies [56]
CD22 B cell malignancies [143]
Her-2 Medulloblastoma [61]
CAIX Renal cell carcinoma [58]
α-Folate receptor Ovarian cancer [57]
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